← Back to patent-cliff list
Nitazoxanide (Genfit)
Tier C — Watch / tradeNitazoxanide (Genfit)
Genfit Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PFOR
Indications (approved)：慢加急性肝衰竭, Decompensated cirrhosis, Liver cirrhosis, Renal impairment, Kidney disease, Liver disease
Regional status
US
Phase II
2018-12-04
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nitazoxanide (Genfit)?
Approved indications include: 慢加急性肝衰竭, Decompensated cirrhosis, Liver cirrhosis, Renal impairment, Kidney disease, Liver disease.
When does the Nitazoxanide (Genfit) patent expire?
No public expiry year is available for Nitazoxanide (Genfit) yet; this page updates once verified.
How do I get a quote for Nitazoxanide (Genfit) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08